<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03301025</url>
  </required_header>
  <id_info>
    <org_study_id>R/17.07.107</org_study_id>
    <nct_id>NCT03301025</nct_id>
  </id_info>
  <brief_title>Pregabalin Effects on Hypotensive Anesthesia During Spine Surgery.</brief_title>
  <official_title>Pregabalin Effects on Hypotensive Anesthesia During Spine Surgery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Elective lumbar spine surgical procedures are commonly performed under controlled hypotension&#xD;
      during general anesthesia. That is beneficial to limit the intraoperative blood loss and&#xD;
      transfusions and improves surgical field. Deliberate hypotension could be achieved via&#xD;
      various medications but mostly associated with significant side effects. Pregabalin&#xD;
      effectively augmented hypotensive anesthesia. The hypothesis is that Pregabalin 150 mg single&#xD;
      preoperative dose may augment intraoperative deliberate hypotension that will be reflected on&#xD;
      blood loss and nitroglycerin consumption.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An arterial line will be established then general anesthesia will be conducted. After&#xD;
      adequate preoxygenation, anesthesia induction by IV fentanyl 1.5µg/kg, propofol 2 mg/kg, and&#xD;
      atracurium 0.5 mg/kg then appropriated size tracheal tube. The ventilator settings will be&#xD;
      adjusted to maintain the end-tidal carbon dioxide tension (ETco2) at 30-35 mm Hg. Anesthesia&#xD;
      will be maintained by isoflurane concentration 1.2%, with 40% oxygen in air then IV infusion&#xD;
      of fentanyl 0.05 mcg/kg/min was started while atracurium 0.1 mg/kg incremental dose as&#xD;
      required. Then patients will be turned into the prone position above pad support permitting&#xD;
      free hanging of the abdomen. Intraoperatively, the target mean arterial arterial blood&#xD;
      pressure (MBP) is 55-65 mm Hg. After surgical incision, if MBP exceeds 65 mm Hg (defined as&#xD;
      hypertension) it will be managed by: increasing isoflurane MAC up to 2%, if no response after&#xD;
      5 min, Nitroglycerin infusion initiated at 0.5 mcg/kg/min to 40 mcg/kg/min. Hypotension (MBP&#xD;
      &lt;55 mm Hg) will be treated by stopping nitroglycerin, proper compensation of losses, reducing&#xD;
      Isoflurane MAC. If persisted; vasoactive drugs will be used. Bradycardia (HR &lt;50 beat/min.),&#xD;
      treated with 0.01 mg/kg atropine IV increments.&#xD;
&#xD;
      The nitroglycerin infusion will be stopped after the finial surgical hemostasis. Fentanyl&#xD;
      infusion will be stopped before ligament sutures. Isoflurane will be closed after the last&#xD;
      surgical suture. After dressing, patient will be turned to the supine position and morphine&#xD;
      0.025 mg/kg IV will be administered then 0.04 mg/kg neostigmine and 0.015 mg/kg atropine for&#xD;
      reversal. Extubation will be done after establishment of acceptable spontaneous respiration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 8, 2018</start_date>
  <completion_date type="Actual">April 30, 2019</completion_date>
  <primary_completion_date type="Actual">March 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nitroglycerin consumption</measure>
    <time_frame>Intraoperative</time_frame>
    <description>the total nitroglycerin consumption in milligram to maintain the target mean arterial pressure (MAP) 55- 65 mmHg.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimated blood loss</measure>
    <time_frame>intraoperative</time_frame>
    <description>towels are weighted, plus suction volume without irrigation fluids in milliter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of transfused blood unites</measure>
    <time_frame>intraoperative</time_frame>
    <description>Packed red blood cell unites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>heart rate (HR)</measure>
    <time_frame>Basal, during intubation, then at 1, 5, 30, 60, 90, 120, 150, 180, 210 minutes post extubation, then postoperatively at 1 and 2 hours.</time_frame>
    <description>in beat/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>end-tidal isoflurane concentration</measure>
    <time_frame>at 30, 60, 90, 120, 150 , 180, 210 minutes after intubation.</time_frame>
    <description>in percent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgeon satisfaction about the field</measure>
    <time_frame>within 2 hours from the end of surgery.</time_frame>
    <description>using a six-point scale (0 = no bleeding, virtually bloodless field; 5 = uncontrolled) bleeding).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedation</measure>
    <time_frame>at 0, 2, 4, 6, 12, 24 hours postoperatively</time_frame>
    <description>(Ramsay sedation scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time to the first request of analgesia.</measure>
    <time_frame>24 hours postoperative</time_frame>
    <description>in hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain</measure>
    <time_frame>at 0, 2, 4, 6, 12, 24 hours postoperatively.</time_frame>
    <description>(VAS 0-10 scale) 10 is the worst pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The total morphine consumption</measure>
    <time_frame>in the 1st 24 hours postoperatively</time_frame>
    <description>in mg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse effects</measure>
    <time_frame>during the first 24 hours postoperatively</time_frame>
    <description>dizziness, headache, nausea and vomiting, or pruritus.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak airway pressures</measure>
    <time_frame>10 minutes after settled prone position</time_frame>
    <description>in centimeter water</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>invasive mean arterial blood pressure (MAP)</measure>
    <time_frame>Basal, during intubation, then at 1, 5, 30, 60, 90, 120, 150, 180, 210 minutes post extubation, then postoperatively at 1 and 2 hours.</time_frame>
    <description>in millimeter mercury (mmHg)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Spine Surgery</condition>
  <arm_group>
    <arm_group_label>Pregabalin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(n=53):</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>(n=53):</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin</intervention_name>
    <description>Pregabalin 150 mg capsule, one h preinduction of general anesthesia</description>
    <arm_group_label>Pregabalin group</arm_group_label>
    <other_name>(LYRICA® 150 mg capsule- PFIZER)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>given a placebo identical capsule once one hour before anesthesia</description>
    <arm_group_label>placebo group</arm_group_label>
    <other_name>control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  American Society of Anesthesiologists (ASA) score I-II&#xD;
&#xD;
          -  admitted to undergo lumbar discectomy or spinal fixation surgery under general&#xD;
             anesthesia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients on anti-hypertensive treatment, diuretics, corticosteroids, pregabalin,&#xD;
             gabapentin, anticonvulsants, antipsychotics,&#xD;
&#xD;
          -  alcohol addiction or drug abuse&#xD;
&#xD;
          -  patients with history of allergy to any drug used in the study .&#xD;
&#xD;
          -  pregnant or nursing women&#xD;
&#xD;
          -  patients with peripheral neuropathy, endocrinal diseases, bleeding abnormality,&#xD;
&#xD;
          -  cardiac, hepatic or renal impairment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alaa Mazy</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Medicine, Mansoura University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Delta Hospital</name>
      <address>
        <city>Mansourah,</city>
        <state>Dakahlia</state>
        <zip>35516</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mansoura University Hospital</name>
      <address>
        <city>Mansourah</city>
        <state>Dakahlia</state>
        <zip>35516</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 26, 2017</study_first_submitted>
  <study_first_submitted_qc>September 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2017</study_first_posted>
  <last_update_submitted>September 16, 2020</last_update_submitted>
  <last_update_submitted_qc>September 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>Alaa Mazy Mazy</investigator_full_name>
    <investigator_title>Associate professor of anesthesia and surgical intensive care</investigator_title>
  </responsible_party>
  <keyword>Pregabalin, hypotensive anesthesia, blood loss, analgesia</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>all data will be available after about 6 months</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Immediately following publication. No end date.</ipd_time_frame>
    <ipd_access_criteria>e mail: alaa_mazy@yahoo.com</ipd_access_criteria>
    <ipd_url>http://alaa_mazy@yahoo.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

